• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
FTT
Click for more information
0.00% 0.5¢

FACTOR THERAPEUTICS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
FTT AGM Results of Meeting27/03/19
FTT Chairman's Address to AGM and Shareholder Presentation27/03/19
FTT Receipt of R&D tax rebatePRICE SENSITIVE22/03/19
FTT Change in substantial holding from PVD21/03/19
FTT Shareholder Update20/03/19
FTT Change in substantial holding12/03/19
FTT Response to ASX QueryPRICE SENSITIVE04/03/19
FTT Change in substantial holding from PVO27/02/19
FTT Letter to Shareholders22/02/19
FTT AGM Notice of Meeting22/02/19
FTT Annual Report for Financial Year to 31 Dec 2018PRICE SENSITIVE21/02/19
FTT Corporate Governance Statement21/02/19
FTT Appendix 4G - Key to Governance Disclosures21/02/19
FTT TOV:Panel Declines to Conduct Proceedings18/02/19
FTT Appendix 3B - lapse of unlisted share options18/02/19
FTT Shareholder Update15/02/19
FTT Cleansing Notice - issue of Placement Shares11/02/19
FTT Appendix 3B clarification - issue date of Placement Shares08/02/19
FTT TOV: Panel Receives Application07/02/19
FTT Change in substantial holding from PVD06/02/19
FTT Becoming a substantial holder05/02/19
FTT Additional placement details for issue of shares under LR71A05/02/19
FTT Cleansing Notice under s708A Corporations Act05/02/19
FTT Appendix 3B - placement shares05/02/19
FTT Placement completed to support future direction of FactorPRICE SENSITIVE05/02/19
FTT Receipt of Notice under S249D Corporations Act05/02/19
FTT Update regarding anticipated R&D tax incentive rebatePRICE SENSITIVE04/02/19
FTT Appendix 4C - December quarterPRICE SENSITIVE31/01/19
FTT Management ChangePRICE SENSITIVE25/01/19
FTT Appendix 3Z - Dr Robert Ryan12/12/18
FTT Change to Board Composition12/12/18
FTT Shareholder Update - Frequently Asked Questions22/11/18
FTT Ceasing to be a substantial holder - Revised21/11/18
FTT Ceasing to be a substantial holder20/11/18
FTT Ceasing to be a substantial holder16/11/18
FTT Conference Call Details - Phase 2 Clinical Trial Results14/11/18
FTT Results of Phase 2 Clinical TrialPRICE SENSITIVE14/11/18
FTT Trading HaltPRICE SENSITIVE13/11/18
FTT Appendix 4C - September 2018 QuarterPRICE SENSITIVE19/10/18
FTT Factor Therapeutics Appoints Transaction AdvisorPRICE SENSITIVE16/10/18
FTT Last patient completes treatment in VLU Ph 2 Clinical TrialPRICE SENSITIVE04/10/18
FTT Shareholder Update Q3 201802/10/18
FTT Phase 2 Trial for Venous Leg Ulcers Nears Completion06/09/18
FTT Half Yearly Report and AccountsPRICE SENSITIVE23/08/18
FTT CEO presentation to Broker Meets Biotech - Perth16/08/18
FTT Appendix 4C - June 2018 quarterPRICE SENSITIVE27/07/18 download Created with Sketch. 139.49KB
FTT CEO Presentation to Bioshares Conference27/07/18 download Created with Sketch. 9.93MB
FTT Recruitment complete in VF00102 Phase 2 clinical trialPRICE SENSITIVE16/07/18 download Created with Sketch. 65.21KB
FTT Screening to close as clinical trial nears completionPRICE SENSITIVE26/06/18 download Created with Sketch. 88.33KB
FTT Clinical Trial UpdatePRICE SENSITIVE14/06/18 download Created with Sketch. 257.19KB
FTT AGM Results of Meeting24/05/18 download Created with Sketch. 101.77KB
FTT Chairman and CEO Address to Annual General Meeting24/05/18 download Created with Sketch. 3.05MB
FTT Receipt of $1.23M R&D tax incentivePRICE SENSITIVE15/05/18
FTT Clinical trial update - recruitment enters final phasePRICE SENSITIVE14/05/18
FTT Ceasing to be a substantial holder04/05/18
FTT Appendix 4C - March 2018 QuarterPRICE SENSITIVE26/04/18
FTT Appendix 3Y - C Behrenbruch24/04/18
FTT Appendix 3Y - C Hirst24/04/18
FTT Appendix 3Y - J Michailidis24/04/18
FTT Change in substantial holding23/04/18
FTT Notice of Annual General Meeting/Proxy Form20/04/18
FTT Appendix 3B - allotment of Rights Issue shares complete19/04/18
FTT Completion of entitlement offer13/04/18
FTT Clinical Trial update - March quarterPRICE SENSITIVE10/04/18
FTT Notice of despatch of Rights Issue documents22/03/18
FTT Appendix 4G for transitional period to 31 December 201722/03/18
FTT Corporate Governance Statement to 31 December 201722/03/18
FTT Annual Report for transitional period to 31 December 201722/03/18
FTT Appendix 3B Rights Issue shares - correction to issue date14/03/18
FTT Rights Issue - Letter to option holders14/03/18
FTT Rights Issue - Letter to ineligible holders14/03/18
FTT Rights Issue - Letter to eligible holders14/03/18
FTT Appendix 3B - Rights Issue Entitlement Offer14/03/18
FTT Rights Issue Entitlement Offer Information BookletPRICE SENSITIVE14/03/18
FTT Factor announces fully underwritten entitlement offerPRICE SENSITIVE14/03/18
FTT Investor PresentationPRICE SENSITIVE14/03/18
FTT Rights Issue Entitlement Offer - Cleansing NoticePRICE SENSITIVE14/03/18
FTT Trading HaltPRICE SENSITIVE12/03/18
FTT Clinical Trial UpdatePRICE SENSITIVE05/03/18
FTT Appendix 4E Preliminary Final ReportPRICE SENSITIVE22/02/18
FTT One-hundredth patient recruited in VF001002 clinical trial08/02/18
FTT Appendix 4C - December 2017 QuarterPRICE SENSITIVE25/01/18
FTT Change in financial year end23/01/18
FTT Clinical Trial UpdatePRICE SENSITIVE18/01/18
FTT Shareholder UpdatePRICE SENSITIVE15/01/18
FTT Change in substantial holding10/01/18
FTT Link Market Services - Change of Brisbane Address18/12/17
FTT Factor receives $3.1M R&D tax rebatePRICE SENSITIVE05/12/17
FTT 50% recruitment reached in VF00102 Clinical TrialPRICE SENSITIVE29/11/17
FTT App 3Y - Director options issued following AGM approval28/11/17
FTT Appendix 3B - issue of options to NED following AGM17/11/17
FTT AGM - Results of Meeting16/11/17
FTT AGM - Chair and CEO Address to Shareholders16/11/17
FTT Clinical Trial UpdatePRICE SENSITIVE02/11/17
FTT Shareholder Information to supplement Report to Shareholders01/11/17
FTT Appendix 4C for the September QuarterPRICE SENSITIVE30/10/17
FTT Notice of Annual General Meeting/Proxy Form13/10/17
FTT Corporate Governance Statement13/10/17
FTT Appendix 4G - Key to Corporate Governance Disclosures13/10/17
FTT Investor call - clinical trial update10/10/17
FTT AGM Results of Meeting
27/03/19
FTT Chairman's Address to AGM and Shareholder Presentation
27/03/19
FTT Receipt of R&D tax rebate
22/03/19PRICE SENSITIVE
FTT Change in substantial holding from PVD
21/03/19
FTT Shareholder Update
20/03/19
FTT Change in substantial holding
12/03/19
FTT Response to ASX Query
04/03/19PRICE SENSITIVE
FTT Change in substantial holding from PVO
27/02/19
FTT Letter to Shareholders
22/02/19
FTT AGM Notice of Meeting
22/02/19
FTT Annual Report for Financial Year to 31 Dec 2018
21/02/19PRICE SENSITIVE
FTT Corporate Governance Statement
21/02/19
FTT Appendix 4G - Key to Governance Disclosures
21/02/19
FTT TOV:Panel Declines to Conduct Proceedings
18/02/19
FTT Appendix 3B - lapse of unlisted share options
18/02/19
FTT Shareholder Update
15/02/19
FTT Cleansing Notice - issue of Placement Shares
11/02/19
FTT Appendix 3B clarification - issue date of Placement Shares
08/02/19
FTT TOV: Panel Receives Application
07/02/19
FTT Change in substantial holding from PVD
06/02/19
FTT Becoming a substantial holder
05/02/19
FTT Additional placement details for issue of shares under LR71A
05/02/19
FTT Cleansing Notice under s708A Corporations Act
05/02/19
FTT Appendix 3B - placement shares
05/02/19
FTT Placement completed to support future direction of Factor
05/02/19PRICE SENSITIVE
FTT Receipt of Notice under S249D Corporations Act
05/02/19
FTT Update regarding anticipated R&D tax incentive rebate
04/02/19PRICE SENSITIVE
FTT Appendix 4C - December quarter
31/01/19PRICE SENSITIVE
FTT Management Change
25/01/19PRICE SENSITIVE
FTT Appendix 3Z - Dr Robert Ryan
12/12/18
FTT Change to Board Composition
12/12/18
FTT Shareholder Update - Frequently Asked Questions
22/11/18
FTT Ceasing to be a substantial holder - Revised
21/11/18
FTT Ceasing to be a substantial holder
20/11/18
FTT Ceasing to be a substantial holder
16/11/18
FTT Conference Call Details - Phase 2 Clinical Trial Results
14/11/18
FTT Results of Phase 2 Clinical Trial
14/11/18PRICE SENSITIVE
FTT Trading Halt
13/11/18PRICE SENSITIVE
FTT Appendix 4C - September 2018 Quarter
19/10/18PRICE SENSITIVE
FTT Factor Therapeutics Appoints Transaction Advisor
16/10/18PRICE SENSITIVE
FTT Last patient completes treatment in VLU Ph 2 Clinical Trial
04/10/18PRICE SENSITIVE
FTT Shareholder Update Q3 2018
02/10/18
FTT Phase 2 Trial for Venous Leg Ulcers Nears Completion
06/09/18
FTT Half Yearly Report and Accounts
23/08/18PRICE SENSITIVE
FTT CEO presentation to Broker Meets Biotech - Perth
16/08/18
FTT Appendix 4C - June 2018 quarter
27/07/18PRICE SENSITIVE download Created with Sketch. 139.49KB
FTT CEO Presentation to Bioshares Conference
27/07/18 download Created with Sketch. 9.93MB
FTT Recruitment complete in VF00102 Phase 2 clinical trial
16/07/18PRICE SENSITIVE download Created with Sketch. 65.21KB
FTT Screening to close as clinical trial nears completion
26/06/18PRICE SENSITIVE download Created with Sketch. 88.33KB
FTT Clinical Trial Update
14/06/18PRICE SENSITIVE download Created with Sketch. 257.19KB
FTT AGM Results of Meeting
24/05/18 download Created with Sketch. 101.77KB
FTT Chairman and CEO Address to Annual General Meeting
24/05/18 download Created with Sketch. 3.05MB
FTT Receipt of $1.23M R&D tax incentive
15/05/18PRICE SENSITIVE
FTT Clinical trial update - recruitment enters final phase
14/05/18PRICE SENSITIVE
FTT Ceasing to be a substantial holder
04/05/18
FTT Appendix 4C - March 2018 Quarter
26/04/18PRICE SENSITIVE
FTT Appendix 3Y - C Behrenbruch
24/04/18
FTT Appendix 3Y - C Hirst
24/04/18
FTT Appendix 3Y - J Michailidis
24/04/18
FTT Change in substantial holding
23/04/18
FTT Notice of Annual General Meeting/Proxy Form
20/04/18
FTT Appendix 3B - allotment of Rights Issue shares complete
19/04/18
FTT Completion of entitlement offer
13/04/18
FTT Clinical Trial update - March quarter
10/04/18PRICE SENSITIVE
FTT Notice of despatch of Rights Issue documents
22/03/18
FTT Appendix 4G for transitional period to 31 December 2017
22/03/18
FTT Corporate Governance Statement to 31 December 2017
22/03/18
FTT Annual Report for transitional period to 31 December 2017
22/03/18
FTT Appendix 3B Rights Issue shares - correction to issue date
14/03/18
FTT Rights Issue - Letter to option holders
14/03/18
FTT Rights Issue - Letter to ineligible holders
14/03/18
FTT Rights Issue - Letter to eligible holders
14/03/18
FTT Appendix 3B - Rights Issue Entitlement Offer
14/03/18
FTT Rights Issue Entitlement Offer Information Booklet
14/03/18PRICE SENSITIVE
FTT Factor announces fully underwritten entitlement offer
14/03/18PRICE SENSITIVE
FTT Investor Presentation
14/03/18PRICE SENSITIVE
FTT Rights Issue Entitlement Offer - Cleansing Notice
14/03/18PRICE SENSITIVE
FTT Trading Halt
12/03/18PRICE SENSITIVE
FTT Clinical Trial Update
05/03/18PRICE SENSITIVE
FTT Appendix 4E Preliminary Final Report
22/02/18PRICE SENSITIVE
FTT One-hundredth patient recruited in VF001002 clinical trial
08/02/18
FTT Appendix 4C - December 2017 Quarter
25/01/18PRICE SENSITIVE
FTT Change in financial year end
23/01/18
FTT Clinical Trial Update
18/01/18PRICE SENSITIVE
FTT Shareholder Update
15/01/18PRICE SENSITIVE
FTT Change in substantial holding
10/01/18
FTT Link Market Services - Change of Brisbane Address
18/12/17
FTT Factor receives $3.1M R&D tax rebate
05/12/17PRICE SENSITIVE
FTT 50% recruitment reached in VF00102 Clinical Trial
29/11/17PRICE SENSITIVE
FTT App 3Y - Director options issued following AGM approval
28/11/17
FTT Appendix 3B - issue of options to NED following AGM
17/11/17
FTT AGM - Results of Meeting
16/11/17
FTT AGM - Chair and CEO Address to Shareholders
16/11/17
FTT Clinical Trial Update
02/11/17PRICE SENSITIVE
FTT Shareholder Information to supplement Report to Shareholders
01/11/17
FTT Appendix 4C for the September Quarter
30/10/17PRICE SENSITIVE
FTT Notice of Annual General Meeting/Proxy Form
13/10/17
FTT Corporate Governance Statement
13/10/17
FTT Appendix 4G - Key to Corporate Governance Disclosures
13/10/17
FTT Investor call - clinical trial update
10/10/17
refresh Created with Sketch. REFRESH
 

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
ASX Market Open: Bessent hype, Lebanon ceasefire hopes push Aus markets higher | November 26, 2024 A rollercoaster ride in on Wall Street @ capped by a Dow Jones record @ and reports of an impending Israel-Hezbollah ceasefire have both buoyed Australian futures, with the ASX 200 expected to rise 0.17% at open today.Forget @Trump trade;” the U.S. rally has been super-charg...
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.